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Abstract
Background: Agricultural environments are contaminated with organic dusts containing bacterial components.
Chronic inhalation of organic dusts is implicated in respiratory diseases. CD14 is a critical receptor for gram-negative
lipopolysaccharide; however, its association with respiratory disease among agricultural workers is unknown. The
objective of this study was to determine if serum soluble CD14 (sCD14) levels are associated with lung function
among agricultural workers and if this association is modified by genetic variants in CD14.
Methods: This cross-sectional study included 584 veterans with >2 years of farming experience and that were
between the ages of 40 and 80 years. Participants underwent spirometry and were genotyped for four tagging
CD14 polymorphisms (CD14/-2838, rs2569193; CD14/-1720, rs2915863; CD14/-651, rs5744455; and CD14/-260,
rs2569190). Serum sCD14 was assayed by ELISA.
Results: Subjects were 98% white males with a mean age 64.5 years. High soluble CD14 levels (> median sCD14)
were associated decreased lung function (FEV1/FVC, p = 0.011; % predicted FEV1, p = 0.03). When stratified by COPD
(yes/no) and smoking status (ever/never), high sCD14 levels (> median sCD14) were associated with low lung
function among ever smokers with COPD (% predicted FEV1, padj = 0.0008; FEV1/FVC, padj = 0.0002). A similar trend
was observed for never smokers with COPD; however, results did not reach statistical significance due to small
sample size. There was a significant sCD14 x COPD/smoking interaction with lung function (% predicted FEV1,
pinter = 0.0498; FEV1/FVC, pinter = 0.011). Regression models were adjusted for age, body mass index, education,
sex, race and years worked on a farm. No association was found between CD14 polymorphisms/haplotypes
(CD14/-2838; CD14/-1720; CD14/-651; CD14/-260) and sCD14 levels. The final model included the variables sCD14
and haplotypes and a haplotype x sCD14 interaction term. Individuals with the GTTG haplotype (CD14/-2838→
CD14/-260) and high sCD14 levels (> median sCD14) had on average 6.94 lower % predicted FEV1 than individuals
with the GCCA haplotype and low sCD14 levels (≤ median sCD14, padj = 0.03).
Conclusion: CD14 haplotypes and sCD14 are important mediators of lung function among those with COPD in this
occupationally-exposed population.
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Background
CD14 is a pattern-recognition receptor and exists as two
distinct forms: as a glycosyl-phosphatidylinositol (GPI) -
anchored membrane protein on the surface of monocytes,
macrophages and neutrophils and as a monocyte or liver-
derived serum soluble protein (sCD14) lacking the GPI
anchor [1]. Soluble CD14 is an acute phase protein [2],
but is also found in normal serum at microgram concen-
trations [3], and confers sensitivity to a gram-negative bac-
terial cell wall component, i.e. lipopolysaccharide (LPS),
for cells lacking membrane CD14, such as endothelial and
epithelial cells [4]. Together with LPS and LPS-binding
protein, CD14 forms a ligand that interacts with the toll-
like receptor – 4 (TLR-4)/MD-2 receptor complex and
leads to activation of innate host defense mechanisms,
stimulating numerous Th1 proinflammatory cytokines, in-
cluding tumor necrosis factor-α (TNF-α) and interleukin-
6 (IL-6) [5]. Recently, it has been suggested that CD14 also
can interact with other pathogen-associated molecular
patterns (PAMPs) such as acylated lipoproteins and pepti-
dioglycan from gram-positive bacteria, and can participate
in the formation of multi-receptor complexes other than
TLR-4, e.g. TLR-1, -2 and -6 [6].
Farming environments are highly contaminated with
airborne inhalable organic dust [7, 8], which contains
PAMPs, including gram-negative and gram-positive bac-
terial components [9, 10]. Forty % of these dust particles
are in the respirable range with a median diameter of
4 μm or less, which may be deposited at the level of the
terminal bronchioles and alveoli [7, 11]. Chronic inhal-
ation of complex organic dust is implicated in respira-
tory disease development and severity, including rhinitis,
sinusitis, asthma-like syndrome, organic dust toxic
syndrome, chronic bronchitis, and chronic obstructive
pulmonary disease (COPD) [12]. Several studies associate
LPS levels in the agricultural environment with adverse
respiratory health outcomes. In healthy individuals, inhal-
ation of purified LPS induces dose-related symptoms, a
decrease in lung function and diffusion capacity, airway
obstruction and both bronchial and systemic inflamma-
tion [13–17].
While these studies suggest an important role of LPS
in respiratory disease pathogenesis, the function of
sCD14, a critical receptor for LPS, in host defense and
respiratory disease among agricultural workers has not
been defined. In fact, no large-scale comprehensive studies
have examined the relationship of sCD14 concentrations
with measures of lung function in occupationally- or non-
occupationally- exposed individuals. The limited numbers
of small studies in non-occupationally exposed adults have
shown that sCD14 levels are elevated in ever smokers and
COPD patients (LPS is a component of cigarette smoke),
and humans experimentally exposed to LPS compared to
healthy non-smokers [14, 18].
Soluble CD14 levels also have been shown to be influ-
enced by CD14 polymorphisms in diverse populations
such as infants, patients with cardiovascular disease,
tuberculosis, periodontal disease and healthy persons
[14, 19–23]. Whether the association between sCD14
levels and lung function is modified by CD14 polymor-
phisms has not been investigated.
As part of the present study, we utilized cross-sectional
data from a well-characterized population of agricultural
workers from the Midwest to determine if sCD14 con-
centration was associated with lung function. We hypoth-
esized that circulating concentrations of sCD14 are
elevated in agricultural workers with impaired lung func-
tion compared to those with higher lung function. We
also examined whether well-characterized polymorphisms
and haplotypes in the CD14 gene modify this association.
Methods
Study population and clinical assessments
This is a cross-sectional study of U.S veterans with agri-
cultural exposure recruited from the outpatient clinics at
the Omaha Veterans Affairs Medical Center. During a
clinic visit, the veteran was asked the following question,
“Have you worked on a farm for more than two years?”
Those who answered “yes” to this question and were
between the ages of 40 and 80 years of age were eligible
for the study. Based on self-report and medical chart
confirmation, participants had no history of asthma,
lung cancer, metastatic cancer to the lungs or interstitial
lung diseases such pulmonary fibrosis, sarcoidosis or
hypersensitivity pneumonitis. Atopy was not assessed in
the participants. Those with a history of an infection or
exacerbation within the previous three weeks were ex-
cluded from the study. Recruitment into the study began
March 2008 and continued through December 2013, with
a total 681 participants. Demographic information, smok-
ing status and years worked on a farm were obtained by
self-report at the time of enrollment. Smokers were de-
fined as having smoked more than 100 cigarettes in their
lifetime [24]. Blood was obtained by venipuncture and
used for cell differentials, serum sCD14 and genomic
DNA isolation. All participants underwent spirometry
with post-bronchodilator spirometry (0.083% albuterol)
performed on veterans with a FEV1/FVC < 0.70.
COPD was defined by the Global Initiative for
Chronic Obstructive Lung Disease (GOLD) classifica-
tion criteria as FEV1/FVC < 0.70 [25]. The highest
recorded FEV1 and FVC were used to derive height-,
weight-, age-, gender- and ethnic- adjusted values
based on National Health and Nutrition Survey
(NHANESIII) reference equations [26]. The study was
approved by the VA Institutional Review Board, and
all participants signed a written informed consent
document before enrollment.
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Soluble CD14 ELISA
Soluble CD14 in serum was quantified using a commer-
cially available kit (DuoSet ELISA development system, R
& D Systems, Inc., Minneapolis, MN, USA) (Supplement
Methods). The limit of detectability was 125 pg/ml.
Genetic analysis
The complete coding region of CD14, intronic sequence,
6 kb of 5’ genomic and 2 kb of 3’ genomic DNA were an-
alyzed, and tagging single nucleotide polymorphisms
(SNPs) were chosen based on a minor allele frequency >
5% and linkage disequilibrium (LD) <0.8 [27]. Additional
SNPs were included based on their functional significance
and relevant citations in the literature. The following SNPs
were analyzed for this study, nomenclature relative to
translation start site: CD14/-2838, rs2569193; CD14/-
1720, rs2915863; CD14/-651, rs5744455; and CD14/-260,
rs2569190. Aliases relative to the transcription start site
are CD14/-2737, CD14/-1619, CD14/-550, and CD14/-
159, respectively. Genomic DNA was isolated from whole
blood using the QiaAMP DNA Blood and Tissue Mini Kit
(Qiagen, Valencia, CA, USA). DNA samples were geno-
typed using matrix-assisted laser desorption/ionization
time-of-flight mass spectrometry (MALDI-TOF; Agena
Bioscience, San Diego, CA, USA). Multiplex polymerase
chain reaction assays and associated extension reactions
were designed using SpectroDesigner software (Agena
Bioscience). Primer extension products were loaded onto
a 384-element chip with a nanoliter pipetting system
(Agena Bioscience) and analyzed with a MassArray
mass spectrometer (Bruker Daltonik GmbH, Bremen,
Germany). The resulting mass spectra were analyzed
for peak identification using SpectroTyperRT 4.0 soft-
ware. For genotyping quality control, Hardy-Weinberg
calculations were performed to ensure that each
marker was within the expected allelic population
equilibrium.
Statistical analyses
Continuous lung function variables (% predicted FEV1
and FEV1/FVC ratio) were compared by patient character-
istics using t-test and ANOVA. Soluble CD14 levels were
categorized at the median value (≤ median, > median) due
to right-handed skew and bimodal distribution; therefore,
a transformation would not be able to normalize the data.
Because of the bimodal distribution, we felt it most appro-
priate to categorize soluble CD14 at the median. Associa-
tions with patient characteristics and lung function
variables were assessed using chi-square and t-tests.
Because smoking history and COPD are directly related to
lung function, a combination variable (COPDsmoke) was
made to assess the interaction between sCD14 and lung
function. COPDsmoke contained 4 categories: 1) COPD,
ever smoker, 2) COPD, never smoker, 3) no COPD, ever
smoker, and 4) no COPD, never smoker. The effect of
sCD14 (≤ median, > median) and COPDsmoke on lung
function was examined in 2-way ANOVA models, with
the lung function variable as the outcome, fixed effects for
sCD14 (≤ median, > median) and COPDsmoke, and
the sCD14 (≤ median, > median) x COPDsmoke inter-
action term included in the model. Multivariable linear
regression models were examined considering the sCD14
(≤ median, > median) x COPDsmoke interaction on lung
function, while adjusting for age, body mass index (BMI),
education, sex, race and years worked on a farm. P-values
for pairwise comparisons were adjusted with Tukey’s
method, a standard technique that considers all possible
pairwise differences of means at the same time.
Associations between sCD14 (≤ median, > median) and
CD14 polymorphisms were assessed using chi-square
tests. The effect of CD14 polymorphisms on lung function
was assessed with univariate ANOVA and multivariable
linear regression. Multiplicative interactions of CD14
polymorphisms x sCD14 (≤ median, > median) or CD14
polymorphisms x COPDsmoke on lung function were
tested, and neither were found to be statistically signifi-
cant. Multivariable models were adjusted for age, BMI,
education, sex, COPD status, race and years worked on a
farm.
CD14 haplotypes were constructed using Haploview
software, and haplotype blocks were estimated using the
confidence interval for R2 values. Haplotypes were defined
as CD14/-2838, CD14/-1720, CD14/-651 and CD14/-260.
The association between sCD14 and CD14 haplotypes was
tested using the R function haplo.score. The effect of a
multiplicative interaction of sCD14 (≤ median, > median)
x CD14 haplotypes on lung function was also evaluated in
regression models, assuming an additive model for the
haplotypes. The interaction between COPDsmoke x CD14
haplotypes was not significant and removed from the
models. Modelling the effect of haplotypes was conducted
with the R package haplo.stats and the haplo.glm and
haplo.score functions. Haplo.glm fits multivariable linear
regressions of lung function on haplotype, allowing for
ambiguous haplotypes, interactions and covariates. This
method performs an iterative two-step expectation-
maximization (EM) algorithm, with the posterior prob-
abilities as weights to update the regression coefficients,
and the regression coefficients are used to update the pos-
terior probabilities . Models that do not include haplotype




Study population characteristics stratified by lung function
(% predicted FEV1 and % FEV1/FVC) are summarized in
Table 1. There were a total of 681 veterans in the
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population; however, only 584 patients had complete data
on pulmonary function measures and covariates. Those
with missing data were excluded in the analysis. Individ-
uals with missing data had similar demographics (age,
BMI, education, sex, race, smoking status, COPD and
mean years worked on a farm) compared to those in-
cluded in the analysis (data not shown). Reflecting demo-
graphic trends of the VA population in the urban Midwest
[28], patients were predominately white males (98%) with
a mean age of 64.8 years. The population included 230 pa-
tients with COPD, as defined by FEV1/FVC < 0.70, and
354 without COPD. Individuals with low pulmonary func-
tion values (% FEV1 and % FEV1/FVC) were more likely to
be older, have lower BMI, have less education, and be ever
smokers. Lung function values were independent of years
worked on a farm, exposure to crops, and exposure to
animals.
Risk factors associated with sCD14 concentration
Soluble CD14 levels were categorized as ≤median or >
median. Age and BMI were determinants of sCD14
levels (Table 2). The mean age for participants with
sCD14 levels > median was greater (66.0 years) com-
pared to those with sCD14 levels ≤median (63.6 years)
(p = 0.0057). Individuals with BMI less than 30 kg/m2
were more likely to have sCD14 levels > median than
those with a BMI ≥ 30 kg/m2 (p = 0.01). Surprisingly,
none of the farming variables (years worked on a farm,
exposure to crops, exposure to animals) were statistically
associated with sCD14 levels.
Association of sCD14 levels with lung function
Because impaired lung function has been shown to be
associated with systemic inflammation and CD14 is a
pivotal receptor for PAMPs found in agricultural dusts,
we investigated the association between serum sCD14
levels and pulmonary function among agricultural
workers. In univariate models we found that there was
an association between sCD14 concentration and the
lung function variables FEV1 (% predicted, p = 0.03) and
FEV1/FVC (%, 0.011) (Table 2). In regression models we
included a sCD14 x COPDsmoke multiplicative inter-
action term because COPD and smoking status are re-
lated to lung function. We found statistically significant
interactions with % predicted FEV1 (pinter = 0.020) and %
FEV1/FVC (pinter = 0.0033) in the unadjusted analysis,
which remained significant after adjusting for covariates
(Fig. 1). Individuals with low % predicted FEV1 or %
FEV1/FVC and >median sCD14 levels were more likely
to be ever/never smokers with COPD compared to those
without COPD.
In a stratified analysis of COPD status and smoking
status, we found an inverse relationship between sCD14
levels and lung function among those with COPD
Table 1 Characteristics of study population by lung function





39-50 38 87.6 (11.8) 74.2 (7.1)
51-60 117 80.8 (18.8) 71.4 (10.9)
61-70 274 80.2 (21.6) 70.3 (11.7)
71-80 155 77.0 (23.3) 66.0 (12.2)
Sex
Male 571 79.6 (21.2) 69.4 (11.7)
Female 13 92.3 (14.1) 77.3 (6.1)
BMI
< 25 86 72.4 (25.9) 61.8 (14.9)
25-29.9 171 81.3 (22.2) 68.5 (11.7)
≥ 30 327 81.2 (18.8) 72.3 (9.5)
Race
White 555 79.8 (21.1) 69.6 (11.7)
Other 23 87.7 (20.9) 71.8 (9.0)
Education
≤ High School 250 77.0 (22.3) 67.3 (12.6)
> High School 311 82.8 (19.6) 71.4 (10.3)
Smoking Status
Ever 463 77.9 (21.4) 68.3 (12.1)
Never 113 88.5 (16.6) 75.2 (6.6)
COPD
No 354 88.6 (16.6) 76.6 (4.3)
Yes 230 66.6 (20.5) 58.9 (11.3)
Steroid Use (Inhaled, Oral)a
No 507 83.4 (18.9) 71.6 (9.7)
Yes 77 56.6 (20.8) 57.0 (15.2
Worked on a Farm, years
< 10 93 76.7 (20.9) 69.5 (11.8)
10-19.9 158 83.1 (18.8) 70.7 (10.3)
20-29.9 92 79.0 (21.5) 68.9 (12.1)
30+ 228 79.5 (22.5) 69.3 (12.2)
Exposure to crops
No 70 77.4 (22.4) 68.9 (12.0)
Yes 499 80.4 (20.9) 69.8 (11.5)
Exposure to animals
No 63 77.0 (22.2) 70.4 (12.0)
Yes 506 80.4 (21.0) 69.6 (11.5)
Abbreviations and Definitions: BMI body mass index (kg/m2), FEV1 forced
expiratory volume in 1 s, % FEV1/FVC FEV1/FVC x 100, FVC forced vital capacity,
COPD FEV1/FVC < 0.70
aIn the last 12 months have you taken inhaled steroids (yes/no), Advair (yes/no)
or Prednisone (yes/no)?
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(Table 3). Among the ever smokers with COPD, there
were statistically significant associations with % pre-
dicted FEV1 (padj = 0.0008) and % FEV1/FVC (padj =
0.0002). We found a similar trend for never smokers
with COPD; however, our sample size was too small to
make statistical inferences. No association between
sCD14 levels and lung function measures among those
without COPD was observed (Table 3). Similar results
were observed when stratifying by COPD status (yes/no)
(Additional file 1: Table S1) or the following three cat-
egories: COPD; no COPD, current smoker; no COPD,
never or former smoker (Additional file 1: Table S2).
Association of CD14 polymorphisms and haplotypes with
sCD14 levels
The study population was genotyped for four polymor-
phisms at locations -2838, -1720, -651, and -260 relative
to the translation start site. The observed minor allele fre-
quencies for the polymorphisms (CD14/-2838, A = 25.7%;
CD14/-651, T = 22.9%; CD14/-260, A = 49.4%; CD14/-
1720, C =42.0%) showed no deviation from a population
in Hardy-Weinberg equilibrium (p > 0.05) and were
consistent with frequencies reported from the HapMap
Project (http:/www.ncbi.nlm.nih.gov/SNP/index.html) in
individuals with Northern and Western European ancestry
(data not shown). Call rate for all polymorphisms was









39-50 22 (8%) 16 (5%) 0.0057
51-60 70 (24%) 47 (16%)
61-70 139 (48%) 135 (46%)
71-80 61 (21%) 94 (32%)
Sex
Male 283 (97%) 288 (99%) 0.16
Female 9 (3%) 4 (1%)
BMI
< 25 34 (12%) 52 (18%) 0.01
25-29.9 77 (26%) 94 (32%)
≥ 30 181 (62%) 146 (50%)
Race
White 275 (95%) 280 (97%) 0.29
Other 14 (5%) 9 (3%)
Education
≤ High School 118 (42%) 132 (48%) 0.15
> High School 166 (58%) 145 (52%)
Smoking Status
Ever 225 (78%) 238 (83%) 0.13
Never 64 (22%) 49 (17%)
COPD
No 181 (62%) 173 (59%) 0.50
Yes 111 (38%) 119 (41%)
Steroid Use (Inhaled, Oral)a
No 260 (89%) 247 (85%) 0.11
Yes 32 (11%) 45 (15%)
FEV1/FVC (mean ± SD) 70.9 ± 10.1 68.4 ± 13.0 0.011
FEV1 (%) (mean ± SD) 81.8 ± 19.4 78.0 ± 22.6 0.030
Worked on a Farm, years
< 10 48 (17%) 45 (16%) 0.23
10-19.9 81 (28%) 77 (27%)
20-29.9 54 (19%) 38 (13%)
30+ 105 (36%) 123 (43%)
Exposure to crops
No 31 (11%) 39 (14%) 0.26
Yes 257 (89%) 242 (86%)
Exposure to animals
No 25 (9%) 38 (14%) 0.06
Yes 263 (91%) 243 (86%)
Abbreviations and Definitions: BMI body mass index (kg/m2),
COPD, FEV1/FVC < 0.70
aIn the last 12 months have you taken inhaled steroids (yes/no), Advair (yes/no)
or Prednisone (yes/no)?
Fig. 1 Interaction of sCD14 and COPD on lung function. X-axis
represents ≤ or >median levels of sCD14. Y-axis represents lung
function (adjusted means and 95% confidence interval). Top. %
predicted FEV1: interaction, padj-inter = 0.0498, Bottom. % FEV1/FVC:
interaction padj-inter = 0.011. Interaction results are adjusted for age,
education, sex, race, BMI and years worked on a farm
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greater than 95%. The pairwise LD between the four poly-
morphisms was r2 < 0.8 (Additional file 2: Figure S1). Five
haplotypes were identified in the population, and their
estimated frequencies were 40.6% for GCCA (-2838,
-1720, -651, -260), 26.9% for ATCG, 23.4% for GTTG,
7.2% for GTCA and 1.8% for other. We did not find an
association between CD14 polymorphisms (CD14/-2838,
p = 0.47; CD14/-1720, p = 0.53; CD14/-651, p = 0.46;
CD14/-260, p = 0.96;) or haplotypes (p = 0.31) with
sCD14 levels (≤ median or > median) in the univariate
or multivariable analysis (n = 584; data not shown).
Association of CD14 polymorphisms and haplotypes with
lung function
We found no significant association between CD14
polymorphisms and lung function (Table 4). In contrast,
we found that the haplotype GTCA was significantly
associated with % FEV1/FVC even after adjustment for
covariates (padj = 0.021). Individuals with the GTCA
haplotype had lower FEV1/FVC than those with the
GCCA haplotype. There was no association of CD14
haplotypes with % predicted FEV1 (Table 4). We did not
find a significant interaction between the COPDsmoke x
CD14 haplotypes on lung function (data not shown).
Analyses were then conducted to examine the sCD14 x
haplotype interaction in relation to % predicted FEV1 or %
FEV1/FVC (Table 5). There was a significant interaction
between the GTTG haplotype and sCD14 for % predicted
FEV1. Individuals with this haplotype and sCD14 levels >
median, have on average, 6.94 lower % predicted FEV1
values than individuals who possess the GCCA haplo-
type and sCD14 levels ≤median (pinter = 0.015). Evidence of
interaction was also observed for the GTCA haplotype,
though of borderline significance (pinter = 0.061). Individuals
with the GTCA haplotype and >median levels of sCD14
have increased FEV1/FVC values than those with the
GTCA haplotype and ≤ sCD14 levels.
Discussion
CD14 is an acute phase protein involved in LPS signal-
ing and therefore is essential for interfacing the innate
immune system with PAMPs. Studies have found that
airway inflammation and decreased pulmonary function
are common among farmers, and these findings are
linked to the presence of LPS in inhaled organic dust
[12]. The importance of CD14 in inflammatory pro-
cesses is underscored by its association with a multitude
of diseases, including sepsis, cardiovascular disease,
periodontitis, tuberculosis and atopic asthma [29–33].
CD14 represents an important mediator of lung function,
as we have shown previously that CD14 haplotypes
(CD14/-1720G or CD14/-260A) are associated with
decreased lung function among those exposed to agricul-
tural environments [34]. The current study presents new
evidence for the relationship between sCD14 levels and
pulmonary function among agricultural workers and
haplotype x sCD14 interaction with lung function.
Specifically we found that sCD14 levels were inversely
related to % predicted FEV1 and FEV1/FVC; however,
this association was found only in COPD patients that
were ever smokers compared to those without COPD
(ever/never smokers). Though there have been no studies
investigating the association between sCD14 levels and
lung function, in a case-control study of nine never
smokers, 10 healthy smokers and 10 COPD patients,
Reguiro et al. showed that sCD14 levels in the bronchoal-
veolar lavage fluid were elevated among healthy smokers
and patients with COPD compared to never-smokers [18].
Table 3 Association of Soluble CD14 Levels with FEV1 & FEV1/FVC: Stratified by COPD and Smoking Status
FEV1(% predicted)
COPD, Ever Smoker COPD, Never smoker No COPD, Ever Smoker No COPD, Never Smoker
sCD14 n Mean ± SE n Mean ± SE n Mean ± SE n Mean ± SE
≤ Median 104 69.8 ± 1.7 7 91.2 ± 6.7 121 88.2 ± 1.6 57 89.1 ± 2.3
> Median 104 60.9 ± 1.7 12 78.0 ± 5.1 134 87.9 ± 1.5 37 90.6 ± 2.9






sCD14 n Mean ± SE n Mean ± SE n Mean ± SE n Mean ± SE
≤ Median 104 61.0 ± 0.74 7 67.0 ± 2.9 121 76.3 ± 0.7 57 77.6 ± 1.0
> Median 104 56.0 ± 0.74 12 62.9 ± 2.2 134 76.3 ± 0.7 37 77.0 ± 1.2





Abbreviations and Definitions: sCD14, soluble CD14; FEV1, forced expiratory volume in 1 s; % FEV1/FVC, FEV1/FVC x 100; FVC, forced vital capacity; COPD, FEV1/FVC
< 0.70; ever smokers, current and former smokers
aMultivariable results (padj) are adjusted for age, body mass index, education, sex, race and years worked on a farm
P-values adjusted for multiple comparisons with Tukey’s method
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We found a similar but non statistically significant rela-
tionship in our agriculturally-exposed population. This
discrepancy is most likely due to measurement of sCD14
levels in two different compartments, the bronchoalveolar
lavage fluid of the lung and blood serum.
The reasons for the association between sCD14
concentration and reduced pulmonary function among
those with COPD are not fully understood, but several
mechanisms may be involved. Reduced lung function
among COPD patients may be responsible, in part, for
the observed systemic inflammation as measured by
sCD14. Inflammatory lung or pulmonary epithelial cells
have been shown to express IL-6. IL-6 may reach the
liver via the bloodstream, stimulating the acute phase
response and production of sCD14 by the liver and
sequentially activating pulmonary inflammatory cells
during transit through the pulmonary circulation. An
alternative mechanism -reverse causation- cannot be
excluded: high levels of cytokines and acute phase
reactants in the peripheral circulation as a consequence
of cigarette smoking may be a cause rather than a
consequence of poor lung function. Persistence of ele-
vated sCD14 concentration and systemic inflammation
may result in damage to the airways, and lower FEV1 of
COPD patients.
The marginal associations between CD14 genotypes
and sCD14 concentrations may not be surprising, given
the equivocal results reported to date. While some studies
have shown significant association of the same tagging
polymorphisms examined in our study with sCD14
concentration, others failed to show any associations
[14, 19, 20, 35–38]. These inconsistencies may be driven
by the complex gene-environment interactions of CD14
expression as well as the use of relatively healthy versus
diseased subjects where any genetic influences on sCD14
are simply overshadowed by other inflammatory stimuli.
The masking of the polymorphism-protein signal via
inflammation was convincingly reported by measuring
sCD14 levels pre- and post- endotoxin inhalation;
CD14/-260 and CD14/-1720 were associated with
sCD14 levels pre-inhalation yet not post-inhalation
[14]. Recently, it has been shown that the association
Table 4 Association of CD14 Polymorphisms and Haplotypes with FEV1 & FEV1/FVC
CD14 Genotype n FEV1 (% Predicted)
Mean ± SD




AA 35 78.3 ± 18.4 0.85 0.98 69.4 ± 10.3 0.97 0.64
AG 228 79.7 ± 21.5 69.5 ± 12.3
GG 316 80.3 ± 21.4 69.7 ± 11.4
rs2915863 CD14/-1720
CC 90 80.7 ± 21.7 0.73 0.65 70.3 ± 10.0 0.20 0.13
CT 293 80.3 ± 20.7 69.8 ± 11.8
TT 180 78.9 ± 21.9 68.6 ± 12.2
rs5744455 CD14/-651
TT 33 85.3 ± 19.5 0.12 0.071 72.9 ± 8.3 0.14 0.12
TC 193 77.8 ± 21.4 68.6 ± 12.5
CC 339 80.4 ± 21.3 69.7 ± 11.6
rs2569190 CD14/-260
AA 134 79.7 ± 21.2 0.71 0.97 70.1 ± 11.4 0.48 0.43
GA 287 79.2 ± 21.7 69.1 ± 12.2
GG 141 81.0 ± 20.2 70.4 ± 11.0
Haplotypeb
GCCA 245c 81.2 ± 1.7 Ref.d Ref. 71.0 ± 1.0 Ref. Ref
ATCG 149 79.9 ± 1.3 0.41 0.62 70.1 ± 0.7 0.28 0.20
GTTG 134 80.7 ± 1.4 0.76 0.37 70.6 ± 0.7 0.61 0.38
GTCA 44 76.4 ± 2.3 0.056 0.25 66.4 ± 1.3 0.001 0.021
Other 12 90.5 ± 3.7 0.014 0.035 71.3 ± 2.1 0.89 0.81
Abbreviations and Definitions: FEV1 forced expiratory volume in 1 s, % FEV1/FVC FEV1/FVC x 100; FVC, forced vital capacity
aMultivariable results (padj) are adjusted for age, BMI, education, sex, COPD status, race and years worked on a farm
bHaplotypes defined as -2838/-1720/-651/-260; Mean ± SE
cSample sizes estimated from haplotype frequency. Mean ± SE are shown
dPairwise comparison to the Base haplotype
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between CD14 polymorphisms and sCD14 levels
decreases from birth to 10 years of age and that this lack
of association is paralleled with a significant increase in
CD14 methylation. Importantly, CD14 methylation levels
were inversely associated with sCD14 levels. Further stud-
ies are necessary to understand the impact of agricultural
exposure and CD14 methylation on sCD14 levels in this
population [38].
There have been a limited number of studies in adults
showing an association between CD14 polymorphisms
and several lung phenotypes such as asthma and allergy
[39, 40], wheeze [41], pulmonary tuberculosis [42] and
pulmonary function [41, 43–45]. While the results of the
present study show a weak association between CD14
polymorphisms and lung function, we found a signifi-
cant interaction between CD14 haplotypes and sCD14
levels on lung function. Many multiplicative interactions
have been found with CD14 polymorphisms and envir-
onmental exposures. In a study of Dutch farmers and
agriculture industry workers, increased environmental
exposure to endotoxin in those with the CD14/-1720 T
or CD14/-260G allele was associated with lower FEV1













Age, yrs -0.09 (0.10) -0.09 (0.10) -0.07 (0.04) -0.08 (0.04)
Body mass index, kg/m3 -0.37 (0.12)* -0.34 (0.12)* 0.14 (0.05)* 0.14 (0.05)*
Sex
Male Referent Referent Referent Referent
Female 6.17 (5.11) 6.79 (5.14) 4.39 (2.17)* 4.55 (2.18)*
Education
≤ High School Referent Referent Referent Referent
> High School 2.51 (1.61) 2.68 (1.62) 1.22 (0.68) 1.12 (0.69)
Race
White Referent Referent Referent Referent
Other 2.97 (3.89) -2.52 (4.42) 0.78 (1.65) 0.23 (1.89)
Worked on Farm, yrs 0.06 (0.04) 0.06 (0.04) 0.01 (0.02) 0.01 (0.02)
COPDSmoke
No COPD, Never smokers Referent Referent Referent Referent
No COPD, Ever smokers 0.01 (2.24) -0.33 (2.25) 0.74 (0.95) -0.84 (0.96)
COPD -22.03 (2.3)* -22.03 (2.31)* -17.13 (0.98)* -17.12 (0.98)*
sCD14
≤ Median Referent Referent Referent Referent
> Median -3.19 (1.57)* 0.51 (3.10) -1.22 (0.66)# -1.66 (1.31)
Haplotypes
GCCA Referent Referent
ATCG - -0.52 (2.00) - -1.32 (0.83)
GTTG 1.81 (1.89) -0.02 (0.80)
GTCA -2.80 (3.32) -4.16 (1.40)*
Other 12.53 (4.78)* 1.73 (2.08)
Interaction
GCCA x ≤Median sCD14 (n = 111) Referent Referent
ATCG x >Median sCD14 (n = 72) - -0.11 (2.83) - 1.39 (1.20)
GTTG x >Median sCD14 (n = 59) -6.94 (2.85)* -1.08 (1.21)
GTCA x >Median sCD14 (n = 24 0.05 (4.45) 3.54 (1.89)#
Other x > Median sCD14 (n = 6) -9.54 (6.46) -3.78 (2.78)
Abbreviations and Definitions: FEV1, forced expiratory volume in 1 s; % FEV1/FVC, FEV1/FVC x 100; FVC, forced vital capacity
^Haplotypes defined as -2838/-1720/-651/-260
*p < 0.05, #p < 0.07
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values compared to those homozygous for the C or A
allele [41]. In contrast, in a study of laboratory animal
workers, those with high endotoxin exposure and the
CD14/-1720C allele had significantly lower lung function
than workers with the TT genotype [43]. In another
study of adults, pack-years of smoking was found to
modify the association between CD14/-260 and lung
function (FEV1 or FEV1/FVC) [45]. In this study, the
CD14/-260AA genotype was associated with lower lung
function in moderate smokers, while heavy smokers with
the CC genotype had decreased lung function [45].
These disparate results underscore the complex nature
of the CD14 gene and the importance of integrating gen-
etic, epigenetic and environmental exposures for under-
standing determinants of the outcome.
A strength of this study is that rather than selecting
only polymorphisms with known biologic function, our
approach involved the use of tagging polymorphisms
with the broader goal of capturing the overall poly-
morphic nature of the gene. Therefore it is possible that
the haplotypes examined in this study and shown to
interact with sCD14 may have little functional biologic
consequence. For instance, the haplotype GTTG was
shown to interact with serum sCD14 levels. Each
polymorphism in this haplotype is found in the pro-
moter region of the CD14 gene, yet only one locus
has been shown to be functional, CD14/-260 [36]. It
is possible that the CD14/-2838, CD14/-1720 and
CD14/-651 are not functional but are merely in LD
with other regions of the gene. The CD14/-260 poly-
morphism has been shown to be functional via modi-
fying the transcriptional activity via SP transcription
factors, with the A allele having more gene expression
than the G allele [36].
To our knowledge, this is the first study to show an
association between sCD14 levels, CD14 haplotypes and
lung function in an occupationally-exposed population.
However the question remains as to whether agricultural
exposure plays a role in our findings. Replication of this
study in participants without agricultural exposure
would be necessary to address this issue. A limitation of
using an exposed population is that a “healthy worker ef-
fect” may have resulted in bias towards the null, because
individuals with respiratory problems may avoid agricul-
tural jobs with the highest exposures. Due to the cross-
sectional nature of this study, we were unable to account
for this type of bias. Furthermore, we were unable to
measure LPS in the occupational setting to determine
whether the association between sCD14 and lung func-
tion was modified by LPS exposure intensity, an area
that warrants further study. In addition our population
was composed of mostly Caucasian males and additional
population studies with other ancestries would be
important information.
Conclusions
In summary, we have shown that levels of sCD14 are in-
versely associated with pulmonary function and are sig-
nificantly modified by CD14 haplotypes among those
with COPD in this agriculturally-exposed population.
Further studies are needed to elucidate the implications
and potential effects of higher circulating levels of
sCD14 in patients with impaired pulmonary function.
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